MENU
+Compare
THNR
ETF ticker: NYSE ARCA
AS OF
Dec 23 closing price
Price
$25.95
Change
+$0.82 (+3.26%)

THNR stock forecast, quote, news & analysis

The investment seeks investment results that generally correspond to the performance of the VettaFi Weight Loss Drug & Treatment Index... Show more

Category: #Health
THNR
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
These past five trading days, the ETF lost 0.00% with an average daily volume of 0 shares traded.The ETF tracked a drawdown of 0% for this period.
Interact to see
Advertisement
A.I.Advisor
a Summary for THNR with price predictions
Dec 24, 2025

THNR's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for THNR turned positive on December 24, 2025. Looking at past instances where THNR's MACD turned positive, the stock continued to rise in of 14 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on December 22, 2025. You may want to consider a long position or call options on THNR as a result. In of 22 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where THNR advanced for three days, in of 82 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 51 cases where THNR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for THNR moved out of overbought territory on December 01, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 7 similar instances where the indicator moved out of overbought territory. In of the 7 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where THNR declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

THNR broke above its upper Bollinger Band on December 23, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), AstraZeneca PLC (NASDAQ:AZN), Merck & Co (NYSE:MRK), Amgen (NASDAQ:AMGN), Pfizer (NYSE:PFE), Teva Pharmaceutical Industries Limited (NYSE:TEVA).

Industry description

The investment seeks investment results that generally correspond to the performance of the VettaFi Weight Loss Drug & Treatment Index. The fund's manager invests at least 80% of its net assets (plus borrowings for investment purposes) in securities that comprise the index. The index is comprised of global companies expected to economically benefit from weight loss drug development. The index includes pharmaceutical manufacturers, manufacturers of combination therapies and telehealth providers who provide access to Amylin agonists and analogs or GLP-1 agonists and analogs, including dual GLP-1 agonists and analogs. The fund is non-diversified.

Market Cap

The average market capitalization across the Amplify Weight Loss Drug & Treatment ETF ETF is 157.63B. The market cap for tickers in the group ranges from 415.28M to 963.92B. LLY holds the highest valuation in this group at 963.92B. The lowest valued company is ALT at 415.28M.

High and low price notable news

The average weekly price growth across all stocks in the Amplify Weight Loss Drug & Treatment ETF ETF was 4%. For the same ETF, the average monthly price growth was 2%, and the average quarterly price growth was 15%. GPCR experienced the highest price growth at 16%, while ALT experienced the biggest fall at -22%.

Volume

The average weekly volume growth across all stocks in the Amplify Weight Loss Drug & Treatment ETF ETF was -51%. For the same stocks of the ETF, the average monthly volume growth was -73% and the average quarterly volume growth was -60%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 53
P/E Growth Rating: 73
Price Growth Rating: 44
SMR Rating: 57
Profit Risk Rating: 67
Seasonality Score: 13 (-100 ... +100)
View a ticker or compare two or three
THNR
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Category Health

Profile
Fundamentals
Details